Your donations help fund the ongoing Post-COVID Research Program and Clinic in BC. Click here to learn more.

Donate to TB Vets Now

  • About Us
    • Respiratory Equipment
    • Research
    • Education
  • How to Help
  • News + Stories
  • Key Tag Program
  • Grants
  • Contact Us
Menu
Donate
Donate
Dr Steve Reynolds and Team - Respiratory Research - TB Vets
Share on facebook
Share on twitter
Share on linkedin

TB Research: Updates from Dr. Yossef Av-Gay

The generosity of TB Vets has helped us achieve significant progress in understanding TB and we have subsequently become one of the leading TB research laboratories in the world.

In past years we discovered and unveiled the role of mycobacterium tuberculosis (Mtb) proteins in mediating infection of the human white blood cells, the macrophages. More recently, we have developed a rapid test for parallel analysis of many potential drug candidates against TB, allowing a quicker and less expensive approach towards drug discovery against this deadly pathogen. Our presentations and publications over the years have gained significant scientific, industrial and media interest.

During the past year, with the help of TB Vets we were able to keep our team working and progressed our research into Host Directed Therapy (HDT) as a novel (new) and innovative approach to combat tuberculosis.

Novel approaches that consider the intracellular nature of Mtb and its interactions with the host are a promising new avenue for drug discovery. Targeting host pathways instead of the pathogen in HDT either increase host antimicrobial capacity, or reduce inflammation, and this approach is gaining more attention as an alternative approach to treat infectious diseases and limit occurrence of anti-microbial drug-resistant TB.

We have carried out an intracellular high-throughput screen (HTS) and identified a specific compound, which kills Mtb within the macrophage (cells) and not in petri dish. The compound induces controlled killing of the infected cells and does not have any effect on non-infected cells.

Our studies lay the groundwork for testing our new compound and progress through a pre-clinical TB drug discovery program. In parallel we have continued our studies of TB basic biology and pathogenicity mechanisms (disease-causing devices).

TB Vets’ support is instrumental to our ability to sustain and progress our multi-year research program. We thank TB Vets Charitable Foundation for their continuous support and help.*

*Topmost Photo: Dr. Av-Gay (front row, second from right) and his team at VGH/UBC

Back to Annual Report 2018-2019
Back to Impact Stories
PrevPrevious Impact StoryTB Vets helps with COVID-19 Testing in BC Interior
Next Impact StoryTB Unit: UpdatesNext

Find us on social media

Facebook
Twitter
Instagram

Subscribe to Updates from the Frontlines

Arming Frontline Medical Heroes 

Keep in touch

Subscribe
Donate Now
Contact us

© 2021 TB Vets Charitable Foundation | Privacy Policy

Registered Charity #87416 1482 RR0001